HCPLive 5 Stories in Under 5: Weekly Audio Recap

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 healthcare headlines for February 09 - 16, 2025:

1. FDA Accepts Lerodalcibep BLA for LDL-C Reduction in High-Risk Patients
   Announced by LIB Therapeutics Inc., the agency has set a PDUFA target action date of December 12, 2025.
2. Travere Therapeutics Plans FSGS Submission for Sparsentan
   An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.
3. Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile
   New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.
4. Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis
   The Phase 2b RENOIR trial met its primary endpoint and key secondary endpoints in patients with RA in new 12-week data.
5. FDA Expands Dosing Label for Avacincaptad Pegol for Geographic Atrophy
   The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.